Увійти

Готові списки джерел за темами / Anti-tumor agent / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Anti-tumor agent.

Статті в журналах з теми "Anti-tumor agent"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Anti-tumor agent".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Chen, Weicui, Bo Liu, Jun Chen, Guoqing Liu, and Xian Liu. "Targeted tumor MRI with gadobutrol-loaded anti-HER2 immunoliposomes." Acta Radiologica 58, no. 5 (2016): 573–80. http://dx.doi.org/10.1177/0284185116664225.

Повний текст джерела

Анотація:

Background Immunoliposomes have been used to deliver MR contrast agents to cancer tissue by targeting tumor associated antigens, thus enabling the visualization of biological processes at the cellular level. Purpose To develop and evaluate the feasibility of specific HER2 targeted liposomal MR contrast agent. Material and Methods Gd-loaded anti-HER2 immunolipomes (Gd-ILs) and non-targeted PEGylated liposomes (Gd-NTLs) were prepared and characterized. Tumor bearing animals were randomized into three groups: Gd- ILs, Gd- NTLs and gadobutrol. Animals were imaged prior and 5, 15, 60, 120 and 180 m

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Fareed, Jawed, Angel Gray, Daniel Kahn, et al. "The effect of tissue factor pathway inhibitor release and interactions with growth factors on the antitumor effects of ultra low molecular weight heparin semuloparin." Journal of Clinical Oncology 30, no. 15_suppl (2012): e13117-e13117. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13117.

Повний текст джерела

Анотація:

e13117 Background: Heparins are known to produce anti-tumor effects beside other pharmacologic actions. More recently an ultra LMWH has been developed for the prevention of thrombosis in cancer patients. Initial studies demonstrated that this agent also exhibits anti-tumor effects in animal models. To understand the mechanism of anti-tumor effects of this agent studies were designed to fractionate this ULMWH in to various AT affinity fractions. Methods: An ULMWH (semuloparin, Sanofi-aventis) and its high (HAF) and low (LAF) affinity fractions were prepare by AT affinity chromatography. These a

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Yamamoto, Satoshi, Eriko Aizu, Hong Jiang, et al. "The potent anti-tumor-promoting agent isoliquiritigenin." Carcinogenesis 12, no. 2 (1991): 317–23. http://dx.doi.org/10.1093/carcin/12.2.317.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Wang, X. L., B. Q. Fu, S. J. Yang, et al. "Trichinella spiralis—A potential anti-tumor agent." Veterinary Parasitology 159, no. 3-4 (2009): 249–52. http://dx.doi.org/10.1016/j.vetpar.2008.10.052.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

OBATA, Rika, and Takeshi OHNUMA. "Electrochemical Oxidation of Anti-tumor Agent, Etoposide." CHEMICAL & PHARMACEUTICAL BULLETIN 41, no. 10 (1993): 1846–47. http://dx.doi.org/10.1248/cpb.41.1846.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Rajabi, Mehdi, Mary Adeyeye, and Shaker A. Mousa. "Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in Cancer." Current Medicinal Chemistry 26, no. 30 (2019): 5664–83. http://dx.doi.org/10.2174/0929867326666190620100800.

Повний текст джерела

Анотація:

:Targeting angiogenesis in the microenvironment of a tumor can enable suppression of tumor angiogenesis and delivery of anticancer drugs into the tumor. Anti-angiogenesis targeted delivery systems utilizing passive targeting such as Enhanced Permeability and Retention (EPR) and specific receptor-mediated targeting (active targeting) should result in tumor-specific targeting. One targeted anti-angiogenesis approach uses peptides conjugated to nanoparticles, which can be loaded with anticancer agents. Anti-angiogenesis agents can suppress tumor angiogenesis and thereby affect tumor growth progre

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Villegas-Vázquez, Edgar Yebrán, Laura Itzel Quintas-Granados, Hernán Cortés, et al. "Lithium: A Promising Anticancer Agent." Life 13, no. 2 (2023): 537. http://dx.doi.org/10.3390/life13020537.

Повний текст джерела

Анотація:

Lithium is a therapeutic cation used to treat bipolar disorders but also has some important features as an anti-cancer agent. In this review, we provide a general overview of lithium, from its transport into cells, to its innovative administration forms, and based on genomic, transcriptomic, and proteomic data. Lithium formulations such as lithium acetoacetate (LiAcAc), lithium chloride (LiCl), lithium citrate (Li3C6H5O7), and lithium carbonate (Li2CO3) induce apoptosis, autophagy, and inhibition of tumor growth and also participate in the regulation of tumor proliferation, tumor invasion, and

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Kakodkar, Nisha C., Radhika Peddinti, Morris Kletzel, et al. "The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth." Pediatric Blood & Cancer 56, no. 1 (2010): 164–67. http://dx.doi.org/10.1002/pbc.22639.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Linot, Camille, Jasmeen Saini, and Prasad S. Adusumilli. "Sustained, cell-intrinsic versus intermittent, cell-extrinsic checkpoint blockade in solid tumor CAR T-cell therapy." Journal of Clinical Oncology 38, no. 5_suppl (2020): 16. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.16.

Повний текст джерела

Анотація:

16 Background: We and others have published that antigen-stress induced functional exhaustion of chimeric antigen receptor (CAR) T cells can be rescued by addition of anti-PD1 agents. To avoid the need for multiple administrations of anti-PD1 agent, we developed CAR T-cell intrinsic PD1 dominant negative receptor (PD1 DNR). Herein, we investigated the anti-tumor efficacy of cell-extrinsic versus intrinsic anti-PD1 strategies. Methods: Human T cells transduced with CD28 costimulated mesothelin-targeted CAR T cells (M28z) with or without anti-PD1 agent, and M28zPD1DNR CAR T cells were investigat

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Samuel, Samson, Elizabeth Varghese, Peter Kubatka, Chris Triggle, and Dietrich Büsselberg. "Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer." Biomolecules 9, no. 12 (2019): 846. http://dx.doi.org/10.3390/biom9120846.

Повний текст джерела

Анотація:

Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-cancer agents individually or in combination with, frequently used, chemotherapeutic agents and/or radiation, owing to the fact that diabetes heightens the risk, incidence, and rapid progression of cancers, including breast cancer, in an individual. In this regard, metformin (1, 1-dimethylbiguanide), well known as ‘Glucophage’ among diabetics, was reported to be cancer preventive while also being a potent anti-proliferative and anti-cancer agent. While meta-analysis studies reported a lower risk and incid

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Lee, Jin-Young, Whasun Lim, and Gwonhwa Song. "Tumor-suppressive function of methiothepin in human placental choriocarcinoma cells." Reproduction 160, no. 6 (2020): 919–29. http://dx.doi.org/10.1530/rep-20-0377.

Повний текст джерела

Анотація:

Placental choriocarcinoma is a malignant trophoblastic tumor associated with placentation. During placentation, complicated molecular networks are mediated by endocrine and paracrine signals. Serotonin neurotransmitters have been identified in the transmembrane region of human placental choriocarcinoma (HPC) cells as tumor promoters; therefore, their antagonists have anti-cancer properties. Although methiothepin, a serotonin receptor antagonist and FDA-approved psychotropic agent, has shown multi-pharmacological functions in various disease models, its anti-tumorigenic activity and mechanisms

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Zheng, Yi-Dan, Ying Zhang, Jun-Yi Ma, Chun-Yan Sang, and Jun-Li Yang. "A Carabrane-Type Sesquiterpenolide Carabrone from Carpesium cernuum Inhibits SW1990 Pancreatic Cancer Cells by Inducing Ferroptosis." Molecules 27, no. 18 (2022): 5841. http://dx.doi.org/10.3390/molecules27185841.

Повний текст джерела

Анотація:

Pancreatic cancer has an extremely poor prognosis, and the clinical drugs for the treatment of pancreatic cancer are usually multi-drug combinations. Therefore, it is necessary to search for and find specific new bioactive agents against pancreatic cancer. Carabrone is a carabrane-type sesquiterpenolide extracted from Carpesium cernuum L., and this natural compound has been reported to be a potential anti-tumor agent. However, there are few reports on the function of carabrone related to anti-tumor activity in pancreatic cancer. Herein, cell experiments indicated that carabrone had anti-prolif

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Yegodayev, Ksenia M., and Moshe Elkabets. "Development of a AXL/PD-1 BiCE as novel immunotherapy agent." South East European Journal of Immunology 8, CITIM (2025): 034. https://doi.org/10.3889/seejim.2025.6095.

Повний текст джерела

Анотація:

Only five to twenty percent of cancer patients respond to anti-PD1 therapy. Recent evidence suggests the involvement of tyrosine kinase receptor AXL in resistance to anti-PD1 therapy, and AXL inhibition sensitize tumors to anti-PD1. In this work we show that AXL expression is associated with exhaustion of CD8T+ cells in the multiple solid cancers, and thus hypothesized that development of Bi-specific-Cell-Engeger (BiCE) antibody that targets AXL and PD1 (BiCE AXL/PD1) will increase the interaction between the AXL-expressing tumor cell and CD8+ T cells and will enhance the anti-tumor lytic acti

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Menéndez-Menéndez, Javier, and Carlos Martínez-Campa. "Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers." International Journal of Endocrinology 2018 (October 2, 2018): 1–20. http://dx.doi.org/10.1155/2018/3271948.

Повний текст джерела

Анотація:

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized and secreted by the pineal gland mainly during the night, since light exposure suppresses its production. Initially, an implication of this indoleamine in malignant disease was described in endocrine-responsive breast cancer. Data from several clinical trials and multiple experimental studies performed both in vivo and in vitro have documented that the pineal hormone inhibits endocrine-dependent mammary tumors by interfering with the estrogen signaling-mediated transcription, therefore behaving as a selective estrogen receptor m

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Dorr, Robert T., Betty K. Samulitis, Lee Wisner, et al. "Characterization of a membrane-active anti-tumor agent, UA8967." Investigational New Drugs 31, no. 3 (2012): 576–86. http://dx.doi.org/10.1007/s10637-012-9901-z.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Cai, Zhun, Chenyang Mao, Yeqing Wang, et al. "Research Progress with Luteolin as an Anti-Tumor Agent." Natural Product Communications 17, no. 11 (2022): 1934578X2211335. http://dx.doi.org/10.1177/1934578x221133579.

Повний текст джерела

Анотація:

In this review, we outline the new expertise and research progress with luteolin as an antitumor agent, and clarify the related results from the aspects of tumor proliferation, apoptosis, invasion, metastasis, sensitivity to radiotherapy and chemotherapy, angiogenesis, and immunotherapy. In recent years, with the development of medical technology, the early detection rate of tumors has increased significantly. However, the number of cancer patients remains high. Therefore, a new and reasonably effective tumor therapeutic drug is urgently demanded. Luteolin, a flavonoid and widespread in nature

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Wu, L., W. Liu, C. Galustian, P. Schafer, A. G. Dalgleish, and J. B. Bartlett. "Effect of lenalidomide on the antiproliferative effect of gemcitabine against pancreatic tumor cells and on immune-mediated pancreatic cancer cell death." Journal of Clinical Oncology 27, no. 15_suppl (2009): e14635-e14635. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e14635.

Повний текст джерела

Анотація:

e14635 Background: Lenalidomide is an immunomodulatory and anti-angiogenic agent that has demonstrated activity against a range of hematological malignancies. Despite evidence of direct anti-proliferative activity against hematological cells in vitro, there is no evidence of single agent direct activity against solid tumor cells in vitro. To take advantage of its known immune-enhancing properties alongside direct anti-tumor agents, lenalidomide is being advanced in solid tumor indications in combination with other agents. There are few data regarding the combination of lenalidomide and standar

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Selvanesan, Benson Chellakkan, Alvaro de Mingo Pulido, Sheelu Varghese, et al. "NSC243928 Treatment Induces Anti-Tumor Immune Response in Mouse Mammary Tumor Models." Cancers 15, no. 5 (2023): 1468. http://dx.doi.org/10.3390/cancers15051468.

Повний текст джерела

Анотація:

NSC243928 induces cell death in triple-negative breast cancer cells in a LY6K-dependent manner. NSC243928 has been reported as an anti-cancer agent in the NCI small molecule library. The molecular mechanism of NSC243928 as an anti-cancer agent in the treatment of tumor growth in the syngeneic mouse model has not been established. With the success of immunotherapies, novel anti-cancer drugs that may elicit an anti-tumor immune response are of high interest in the development of novel drugs to treat solid cancer. Thus, we focused on studying whether NSC243928 may elicit an anti-tumor immune resp

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Gerber, Hans-Peter, and Napoleone Ferrara. "Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies." Cancer Research 65, no. 3 (2005): 671–80. http://dx.doi.org/10.1158/0008-5472.671.65.3.

Повний текст джерела

Анотація:

Abstract Preclinical models have examined the pharmacologic and pharmacodynamic activities of an anti–vascular endothelial growth factor (VEGF) humanized, monoclonal antibody, bevacizumab, and/or its murine equivalent A4.6.1. These studies found that single-agent therapy with bevacizumab/A4.6.1 resulted in tumor growth inhibition of 20 different human tumor cell lines (13 tumor types) implanted into nude mice irrespective of the route of administration or tumor location. Several of these studies also observed significant inhibition of tumor metastases. Various studies have examined the feasibi

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Gephart, Benjamin D., Don W. Coulter, and Joyce C. Solheim. "Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity." International Journal of Molecular Sciences 26, no. 13 (2025): 6440. https://doi.org/10.3390/ijms26136440.

Повний текст джерела

Анотація:

Cyclophosphamide (CPX) is an alkylating agent commonly used for various hematological and solid malignancies. In addition to its use as a cytotoxic agent to directly kill tumor cells, numerous immunomodulatory properties of CPX in the tumor microenvironment (TME) of several cancer types have also been documented. These properties include the selective depletion of immune-suppressive regulatory T cells (Tregs), triggering of immunogenic cell death (ICD) and enhanced antigen presentation, and release of type I interferons (IFNs). Moreover, preclinical models as well as human clinical trials have

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Bennett, Kaila M., Jacob P. Matson, Sylwia Stopka, et al. "Abstract 6161: Exploring BRG399, a novel microtubule-binding agent, as an inducer of immunogenic cell death in cancer therapy." Cancer Research 85, no. 8_Supplement_1 (2025): 6161. https://doi.org/10.1158/1538-7445.am2025-6161.

Повний текст джерела

Анотація:

Abstract Cancer therapy is transforming from traditional chemotherapeutic agents (CTAs) to innovative immunotherapies. Despite this shift, chemotherapy remains clinically stable, as CTAs are thought to convert the tumor microenvironment (TME) from immunosuppressive to immune-active by inducing immunogenic cell death (ICD) in tumor cells which leads to stimulation of immune cells. This ICD induction is thought to be crucial for enhancing the efficacy of immunotherapies. Thus, using CTAs as ICD agents—alone or in combination with immunotherapies—may offer significant anti-cancer benefits and new

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Felińska, Zuzanna, Julia Silldorff, Tomasz Fura, et al. "Ulcerative colitis - ustekinumab as a new biologic therapy, review 2024." Quality in Sport 17 (August 16, 2024): 53670. http://dx.doi.org/10.12775/qs.2024.17.53670.

Повний текст джерела

Анотація:

Biologic agents have significantly transformed the therapeutic approach to ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the pioneering biologic drugs introduced to induce and maintain remission in this inflammatory bowel disease. Recently, ustekinumab, another biologic option, has been approved for the treatment of moderate-to-severe ulcerative colitis. Ustekinumab demonstrates a favorable clinical efficacy and safety profile for the treatment of moderately to severely active ulcerative colitis. As the first biologic agent to target the IL-12/IL-23 pathways, ustekinumab rep

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Oshikawa, Tetsuya, Masato Okamoto, Tomoyuki Tano, et al. "Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent." International Immunopharmacology 6, no. 5 (2006): 764–73. http://dx.doi.org/10.1016/j.intimp.2005.11.010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Liang, Jiabao, Tong Wen, Xiaojian Zhang, and Xiaoling Luo. "Chlorogenic Acid as a Potential Therapeutic Agent for Cholangiocarcinoma." Pharmaceuticals 17, no. 6 (2024): 794. http://dx.doi.org/10.3390/ph17060794.

Повний текст джерела

Анотація:

Chlorogenic acid (CGA) has demonstrated anti-tumor effects across various cancers, but its role in cholangiocarcinoma (CCA) remains unclear. Our study revealed CGA’s potent anti-tumor effects on CCA, significantly suppressing cell proliferation, migration, colony formation, and invasion while inhibiting the epithelial–mesenchymal transition. CGA induced apoptosis, modulated cell cycle progression, and exhibited a stable binding affinity to AKR1B10 in CCA. AKR1B10 was highly expressed in RBE cells, and CGA treatment reduced AKR1B10 expression. Knocking out AKR1B10 inhibited the proliferation of

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Luchtel, Rebecca A., Tushar Bhagat, Kith Pradhan, et al. "High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model." Proceedings of the National Academy of Sciences 117, no. 3 (2020): 1666–77. http://dx.doi.org/10.1073/pnas.1908158117.

Повний текст джерела

Анотація:

Major efforts are underway to identify agents that can potentiate effects of immune checkpoint inhibition. Here, we show that ascorbic acid (AA) treatment caused genomewide demethylation and enhanced expression of endogenous retroviral elements in lymphoma cells. AA also increased 5-hydroxymethylcytosine (5hmC) levels of CD8+ T cells and enhanced their cytotoxic activity in a lymphoma coculture system. High-dose AA treatment synergized with anti-PD1 therapy in a syngeneic lymphoma mouse model, resulting in marked inhibition of tumor growth compared with either agent alone. Analysis of the intr

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Dahlem, Charlotte, Wei Xiong Siow, Maria Lopatniuk, et al. "Thioholgamide A, a New Anti-Proliferative Anti-Tumor Agent, Modulates Macrophage Polarization and Metabolism." Cancers 12, no. 5 (2020): 1288. http://dx.doi.org/10.3390/cancers12051288.

Повний текст джерела

Анотація:

Natural products represent powerful tools searching for novel anticancer drugs. Thioholgamide A (thioA) is a ribosomally synthesized and post-translationally modified peptide, which has been identified as a product of Streptomyces sp. MUSC 136T. In this study, we provide a comprehensive biological profile of thioA, elucidating its effects on different hallmarks of cancer in tumor cells as well as in macrophages as crucial players of the tumor microenvironment. In 2D and 3D in vitro cell culture models thioA showed potent anti-proliferative activities in cancer cells at nanomolar concentrations

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Jin, Chengwen, Mingyuan Yuan, Hualei Bu, and Chengjuan Jin. "Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy." Journal of Oncology 2022 (April 12, 2022): 1–15. http://dx.doi.org/10.1155/2022/4880355.

Повний текст джерела

Анотація:

Angiogenesis is one of the hallmarks of cancer and plays a crucial role in carcinogenesis and progression of epithelial ovarian cancer. Antiangiogenic agent is the first approved targeted agent in ovarian cancer. Anti-angiogenic agents mainly include agents target VEGF/VEGFR pathway, such as bevacizumab and agents target receptor tyrosine kinase, and non-VEGF/VEGFR targets of angiogenesis. Antiangiogenic agents demonstrate certain effects in ovarian cancer treatment either as monotherapy or combined with chemotherapy. Unfortunately, antiangiogenic agents, such as bevacizumab, integrated into t

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Miyake, Yasuhiro, Hiroshi Matsushita, and Kazuhide Yamamoto. "Anti-60S ribosomal protein L29 antibody: New anticancer agent discovered from human sera." Journal of Clinical Oncology 31, no. 15_suppl (2013): 3071. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3071.

Повний текст джерела

Анотація:

3071 Background: Incidence of hepatocellular carcinoma (HCC) is lower in autoimmune hepatitis (AIH) than chronic viral hepatitis. In AIH, serum immunoglobulin G (IgG) levels are associated with the clinical features. In this study, we searched IgG showing anti-tumor effect in sera of AIH patients. Methods: Total IgG was extracted from sera of AIH patients by using protein G. Anti-tumor effects of the total IgG were evaluated by MTT assay using human HCC Huh7 cells and PLC/PRF/5 cells. Autoantigens in membrane proteins of Huh7 cells were screened by immunoprecipitation followed by liquid chroma

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Schaefer, Christopher W., Deepika Lal, R. Robert Vethanayagam, Joseph A. Spernyak, Mukund Seshadri, and Eunice S. Wang. "Anti-Vascular and Anti-Tumor Effects of the Vascular Disrupting Agent ASA404 (DMXAA) in Human Acute Leukemia Xenograft Models." Blood 118, no. 21 (2011): 4293. http://dx.doi.org/10.1182/blood.v118.21.4293.4293.

Повний текст джерела

Анотація:

Abstract Abstract 4293 Acute leukemia growth and expansion within the marrow microenvironment is linked to increased vascularization. Vascular delivery of chemotherapy drugs within the marrow space may also be an important mediator of anti-leukemic activity. We examined the effects of a tumor -vascular disrupting agent (tumor-VDA), ASA404 (DMXAA; Vadimezan), against human acute leukemia alone and in combination with anthracycline therapy. Exposure of human acute leukemia cells (HEL, Raji) to ASA404 (200–1000 mM) in vitro for up to 72 hours resulted in no evidence of direct cytotoxicity. Howeve

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Sanna, Daniele, Maria Serra, Valeria Ugone, et al. "Biorelevant reactions of the potential anti-tumor agent vanadocene dichloride." Metallomics 8, no. 5 (2016): 532–41. http://dx.doi.org/10.1039/c6mt00002a.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Jiang, Hong, Satoshi Yamamoto, Kiyotako Nishikawa, and Ryuichi Kato. "Anti-tumor-promoting action of FK506, a potent immunosuppressive agent." Carcinogenesis 14, no. 1 (1993): 67–71. http://dx.doi.org/10.1093/carcin/14.1.67.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Jiang, Hong, Satoshi Yamamoto, Kiyotaka Nishikawa, and Ryuichi Kato. "Anti-tumor-promoting action of FK506, a potent immunosuppressive agent." Japanese Journal of Pharmacology 58 (1992): 160. http://dx.doi.org/10.1016/s0021-5198(19)48980-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Melendez, Robert, Joseph Harrison, Eric Rowinsky, Lisa Hammond, and Thomas Fitzsimmons. "Acute retinal toxicity from the novel anti-tumor agent, Irofulven." Documenta Ophthalmologica 108, no. 3 (2004): 249–51. http://dx.doi.org/10.1007/s10633-004-4085-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al. "Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models." Haematologica 105, no. 11 (2020): 2584–91. http://dx.doi.org/10.3324/haematol.2019.227215.

Повний текст джерела

Анотація:

Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody drug conjugate MEN1309/OBT076 targeting CD205. The study included preclinical in vitro activity screening on a large panel of cell lines, both as single agent and in combination and validation experiments on in vivo models. CD205 was first shown frequently expressed in lymphomas, leukemias and multiple myeloma by immunohistochemistry on tissue microarrays. Anti-tumor activity of MEN1

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Xia, Yi, Fuling Zhou, Liang Kong та ін. "Primary analysis of a phase 1/2 study of LM-101: An anti-SIRPα antibody as a single agent in patients with advanced malignancies." Journal of Clinical Oncology 42, № 16_suppl (2024): 2640. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.2640.

Повний текст джерела

Анотація:

2640 Background: LM-101 is a humanized monoclonal antibody which binds to both V1 and V2 isoforms of SIRPα that expressed on macrophages and dendritic cells and enables phagocytosis of tumor cells. LM-101 has shown optimal pre-clinical safety profiles and promising anti-tumor activity in animal models. Here we report the primary analysis of the single agent dose escalation results of a phase 1/2 study (NCT05615974). Methods: This is an open-label, phase 1/2, first-in-human, multicenter dose escalation study with dose expansion evaluating safety and clinical activity of LM-101 as a single agent

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Chaibi, Assia, Christophe Rey, Alban Bessede, and Imane Nafia. "Abstract B074: Enhanced anti-tumor response to anti-angiogenic/hypoxia-regulating therapies in combination with immune checkpoint blockade in a murine model of renal carcinoma." Cancer Immunology Research 13, no. 2_Supplement (2025): B074. https://doi.org/10.1158/2326-6074.io2025-b074.

Повний текст джерела

Анотація:

Abstract Background: While antiangiogenic & other targeted therapies have been shown effective in preclinical & clinical trials, tumors can acquire resistance thereby conferring them the ability to survive and grow under hypoxic conditions. Hence, combining angiogenesis- and/or hypoxia-targeted strategies with immune checkpoint inhibitors (anti-PD1/PDL1) are of particular interest as these approaches might overcome resistance or enhance the immune system's ability to attack tumor cells. Methods: Using the murine syngeneic RENCA tumor model, this study investigated the effects of an ant

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Raben, David, Cataldo Bianco, Vincenzo Damiano, et al. "Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model." Molecular Cancer Therapeutics 3, no. 8 (2004): 977–83. http://dx.doi.org/10.1158/1535-7163.977.3.8.

Повний текст джерела

Анотація:

Abstract Objective: Targeting the tumor vasculature may offer an alternative or complementary therapeutic approach to targeting growth factor signaling in lung cancer. The aim of these studies was to evaluate the antitumor effects in vivo of the combination of ZD6126, a tumor-selective vascular-targeting agent; ZD1839 (gefitinib, Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor; and ionizing radiation in the treatment of non-small cell lung cancer xenograft model. Methods: Athymic nude mice with established flank A549 human non-small cell lung cancer xenograft model xenog

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Pollard, Rachel E., Amy R. Sadlowski, Susannah H. Bloch, et al. "Contrast-assisted Destruction-replenishment Ultrasound for the Assessment of Tumor Microvasculature in a Rat Model." Technology in Cancer Research & Treatment 1, no. 6 (2002): 459–70. http://dx.doi.org/10.1177/153303460200100606.

Повний текст джерела

Анотація:

Angiogenesis, the development of new blood vessels, is necessary for tumor growth. Anti-angiogenic therapies have recently received attention as a possible cancer treatment. The purpose of this study was to monitor the vascularity of induced tumors in rats using contrast-enhanced ultrasound during anti-angiogenic therapy. Six rats with subcutaneously implanted R3230 murine mammary adenocarcinomas were treated with an orally administered anti-angiogenic agent (SU11657) beginning 28 days after tumor implantation (20 mg/kg BW once daily). Three additional tumor-bearing control rats were treated w

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Valantin, Marc-Antoine, Léna Royston, Maxime Hentzien, et al. "Therapeutic Perspectives in the Systemic Treatment of Kaposi’s Sarcoma." Cancers 14, no. 3 (2022): 484. http://dx.doi.org/10.3390/cancers14030484.

Повний текст джерела

Анотація:

In patients with Kaposi’s sarcoma (KS), the therapeutic goal is to achieve a durable remission in the size and number of skin and visceral lesions. Although most patients show tumor regression in response to standard systemic chemotherapy regimens, alternative systemic treatments are needed for patients who develop refractory KS. Anti-angiogenic therapies represent attractive therapeutic targets in this context, due to the central role of angiogenesis in KS pathogenesis. Pomalidomide, which exhibits such anti-angiogenic activity through inhibition of VEGF, currently constitutes the most promis

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Zhang, M., J. Huck, M. Hyer, J. Ecsedy, and M. Manfredi. "Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models." Journal of Clinical Oncology 27, no. 15_suppl (2009): 8553. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.8553.

Повний текст джерела

Анотація:

8553 Background: Aurora A kinase is a serine/threonine protein kinase that is essential for the successful transit of cells through mitosis. MLN8237 is a selective small molecule inhibitor of Aurora A kinase that has demonstrated anti-tumor activity in animal models of solid human tumors. In this study we explored the anti-tumor effect of MLN8237 in vivo in pre-clinical models of human Diffuse Large B-cell Lymphoma (DLBCL) both as a single agent and in combination with the anti-CD20 monoclonal antibody Rituximab. Methods: Three human DLBCL models were examined in SCID mice. In two of the model

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Neuwelt, E. A., and E. Frenkel. "The paradoxical effect of targeted antivascular agents in the therapy of CNS malignancies." Journal of Clinical Oncology 27, no. 15_suppl (2009): 2013. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.2013.

Повний текст джерела

Анотація:

2013 Background: The rationale of vascular targeted agents (i.e., inhibitors of vascular endothelial growth factors [VEGF] or endothelial intergrins) in the therapy of central nervous system (CNS) malignancies is based upon the concept that normalization of tumor vasculature, with a decrease in tumor interstitial pressure, will improve access of cytoreductive drugs. However, previous studies in our laboratory have raised the serious concern that these agents rapidly normalize the blood-brain barrier (BBB) and therefore may result in restoration of the low permeability characteristics of the BB

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Lindquist, Jeffrey N., Kai Qin, Aaron M. Ring, and Hirdesh Uppal. "Abstract 4073: Decoy-resistant IL-18 enhances checkpoint inhibitor combinations beyond anti-PD-1 in vitro and in vivo." Cancer Research 84, no. 6_Supplement (2024): 4073. http://dx.doi.org/10.1158/1538-7445.am2024-4073.

Повний текст джерела

Анотація:

Abstract Background: Interleukin-18 (IL18) is a proinflammatory cytokine that modulates both innate and adaptive immune responses. Historically, wild-type recombinant IL-18 has shown limited anti-tumor efficacy in preclinical models and clinical trials, likely due to upregulation of IL-18 binding protein (IL-18BP), a negative regulator of the IL-18 signaling axis. Accordingly, an engineered IL-18 cytokine capable of interacting with the IL-18 receptor, but resistant to IL-18BP interactions (i.e., “Decoy-Resistant IL-18”, DR-18), has demonstrated enhanced therapeutic potential in mouse tumor mo

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Du, Yong, Aditya Kulkarni, Jianli Zhou, Hui Dai, Kishor Bhatia, and Shiaw-Yih Lin. "Abstract A044: LP-184, a Novel Acylfulvene, Sensitizes Immuno-refractory Triple-Negative Breast Cancers (TNBCs) To Anti-PD1 Therapy by Affecting the Tumor Microenvironment." Cancer Immunology Research 13, no. 2_Supplement (2025): A044. https://doi.org/10.1158/2326-6074.io2025-a044.

Повний текст джерела

Анотація:

Abstract Drugs that induce DNA double strand breaks (DSBs) can activate the cGAS/STING pathway, leading to immune responses. Lantern Pharma is advancing a novel acylfulvene small molecule therapeutic, LP-184, a DNA damaging alkylating agent that creates DNA DSBs. LP-184 is a prodrug requiring bioactivation by the enzyme prostaglandin reductase 1 (PTGR1). RNAseq analysis of cancer cells exposed to LP-184 revealed activation of the STING pathway. A link between replication stress response (RSR) defect signature and enhancement of anti-PD1 activity in mouse models implicated certain DNA Damage Re

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Kwong, Brandon, Haipeng Liu, and Darrell Irvine. "Intratumoral delivery of liposome-anchored anti-CD137 and IL-2 induces highly potent local and systemic anti-tumor immunity while minimizing toxic inflammatory side effects (165.6)." Journal of Immunology 188, no. 1_Supplement (2012): 165.6. http://dx.doi.org/10.4049/jimmunol.188.supp.165.6.

Повний текст джерела

Анотація:

Abstract Immunostimulatory cytokines and antibodies induce potent anti-tumor immune responses in animal models, but also elicit dose-limiting systemic inflammatory toxicity, limiting their effectiveness in the clinic. To address this limitation, we developed a strategy to anchor immunotherapeutics to the surface of lipid nanoparticles (NPs), thus restricting their biodistribution following local injection. We previously demonstrated that NP-coupled anti-CD40 and CpG oligos significantly inhibited growth of s.c. B16F10 tumors, while minimizing systemic exposure to these agents and eliminating t

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Rice, Audie G., Myles B. C. Dillon, Anne M. Van Abbema, and Daniel E. H. Afar. "HuLuc63 in Combination Regimens with Conventional and Targeted Therapies Has Additive and Synergistic Anti-Tumor Activity in Pre-Clinical Models of Myeloma." Blood 110, no. 11 (2007): 2517. http://dx.doi.org/10.1182/blood.v110.11.2517.2517.

Повний текст джерела

Анотація:

Abstract Introduction: HuLuc63 is a humanized monoclonal antibody that targets CS1 (CD2 subset 1, CRACC, SLAMF7, CD319), a cell surface glycoprotein that is highly and universally expressed on myeloma cells. In preclinical studies, we have shown that HuLuc63 treatment of mice with multiple myeloma (MM) xenograft tumors resulted in significant in vivo anti-tumor activity that is mediated at least in part by an antibody-dependent cellular cytotoxicity (ADCC) mechanism of action. The purpose of this study was to examine whether using HuLuc63 in combination with a panel of drugs having distinct mo

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Wang, Ju Bo, Mao De Wang, En Xiao Li, and Dan Feng Dong. "Advances and prospects of anginex as a promising anti-angiogenesis and anti-tumor agent." Peptides 38, no. 2 (2012): 457–62. http://dx.doi.org/10.1016/j.peptides.2012.09.007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Tachibana, Tomoko, Tomoko Gowa Oyama, Yukie Yoshii, et al. "An In Vivo Dual-Observation Method to Monitor Tumor Mass and Tumor-Surface Blood Vessels for Developing Anti-Angiogenesis Agents against Submillimeter Tumors." International Journal of Molecular Sciences 24, no. 24 (2023): 17234. http://dx.doi.org/10.3390/ijms242417234.

Повний текст джерела

Анотація:

Managing metastasis at the early stage and detecting and treating submillimeter tumors at early metastasis are crucial for improving cancer prognosis. Angiogenesis is a critical target for developing drugs to detect and inhibit submillimeter tumor growth; however, drug development remains challenging because there are no suitable models for observing the submillimeter tumor mass and the surrounding blood vessels in vivo. We have established a xenograft subcutaneous submillimeter tumor mouse model with HT-29-RFP by transplanting a single spheroid grown on radiation-crosslinked gelatin hydrogel

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Cooper, Jalyn, Dheeraj Kodali, and Gerald M. Higa. "Acute encephalopathy with combination dabrafenib/trametinib therapy." Journal of Oncology Pharmacy Practice 23, no. 4 (2016): 313–17. http://dx.doi.org/10.1177/1078155216638551.

Повний текст джерела

Анотація:

Biomarkers have improved the clinical application of numerous targeted agents used to treat solid tumors. In melanoma, the finding that approximately 60% of tumor cells harbor specific Val600 mutations of BRAF has increased the likelihood of response to certain agents aimed at inhibiting the mutant kinase. While dabrafenib is an effective anti-tumor agent with acceptable tolerability in patients with BRAF-mutated melanoma, we report the development (and outcome) of a previously unpublished acute toxic reaction observed in a patient receiving the drug.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Yigit, Burcu, Xavier Michelet, Shalu Kharkwal, et al. "164 AgenT-797, a novel allogenic and ‘off-the shelf’ iNKT cell therapy promotes effective tumor killing." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A177. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0164.

Повний текст джерела

Анотація:

BackgroundHarnessing both the innate and adaptive immune system could increase the efficiency of current cancer immunotherapies and promote durable anti-tumor immunity. Invariant natural killer T (iNKT) cells are innate-like lymphocytes that bridge innate and adaptive immune responses and promote anti-cancer immunity. iNKT cells are activated and respond rapidly via multiple signals such as recognition of lipid antigens through the invariant T cell receptor (TCR), pro-inflammatory cytokines or recognition of stress ligands. Here we describe, AgenT-797, a novel, allogeneic and ‘off-the shelf’ i

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Capello, Michela, Angelica Sette, Theo Plantinga, et al. "Abstract 3283: GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity." Cancer Research 83, no. 7_Supplement (2023): 3283. http://dx.doi.org/10.1158/1538-7445.am2023-3283.

Повний текст джерела

Анотація:

Abstract GEN1046 (DuoBody®-PD-L1x4-1BB) is an investigational, potential first-in-class bispecific immunomodulatory antibody designed to elicit an anti-tumor immune response by simultaneous and complementary blockade of PD-L1 on tumor or immune cells and conditional 4-1BB stimulation on T cells and NK cells. Previously, we described encouraging preclinical and early clinical activity of GEN1046 (Muik, et al., 2022, Cancer Discovery). We hypothesized that combining GEN1046 with PD-1 blockade would further potentiate anti-tumor activity through distinct and complementary immune modulatory effect

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!